| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | phenformin | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.4 |